Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 3
1967 3
1968 2
1969 6
1970 7
1971 4
1972 7
1973 6
1974 1
1975 3
1976 3
1977 5
1978 3
1979 4
1980 3
1981 4
1982 1
1983 2
1984 4
1985 4
1986 1
1987 5
1988 6
1989 6
1990 2
1991 3
1992 2
1993 1
1994 4
1995 3
1996 8
1997 11
1998 10
1999 15
2000 8
2001 10
2002 20
2003 5
2004 13
2005 12
2006 14
2007 19
2008 14
2009 18
2010 8
2011 10
2012 7
2013 13
2014 13
2015 3
2016 11
2017 8
2018 5
2019 4
2020 4
2021 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

362 results

Results by year

Filters applied: . Clear all
Page 1
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Among authors: hanefeld m. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Among authors: hanefeld m. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189509 Clinical Trial.
[Multimodal therapy of dyslipidemia].
Stahn A, Hanefeld M. Stahn A, et al. Among authors: hanefeld m. Clin Res Cardiol Suppl. 2011 May;6:10-6. doi: 10.1007/s11789-011-0031-5. Clin Res Cardiol Suppl. 2011. PMID: 22528173 Review. German.
Insulin and atherosclerosis: how are they related?
Monnier L, Hanefeld M, Schnell O, Colette C, Owens D. Monnier L, et al. Among authors: hanefeld m. Diabetes Metab. 2013 Apr;39(2):111-7. doi: 10.1016/j.diabet.2013.02.001. Epub 2013 Mar 15. Diabetes Metab. 2013. PMID: 23507269 Review.
The future of the metabolic syndrome.
Schwarz PE, Bornstein SR, Hanefeld M. Schwarz PE, et al. Among authors: hanefeld m. Horm Metab Res. 2009 Feb;41(2):73-4. doi: 10.1055/s-0029-1192042. Epub 2009 Feb 12. Horm Metab Res. 2009. PMID: 19214919 No abstract available.
Safety profile of pioglitazone.
Hanefeld M, Belcher G. Hanefeld M, et al. Int J Clin Pract Suppl. 2001 Sep;(121):27-31. Int J Clin Pract Suppl. 2001. PMID: 11594241 Review.
362 results